Q-omics provides the consensus-scored SNORA71D profile across patient tissues and cancer cell-line models. SNORA71D expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, SNORA71D is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, SNORA71D RNA expression shows 10,109 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, COAD, and UVM as cancer lineages where SNORA71D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA71D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA71D survival associations across molecular data types. SNORA71D RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA71D RNA expression–survival associations across cancer types. High SNORA71D expression shows unfavorable associations in THCA, UVM, THYM, OV, LUSC and KICH. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for SNORA71D RNA expression.
This table summarizes SNORA71D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA71D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA71D shows higher tumor expression in COAD, HNSC, STAD, LUSC, KIRC and LUAD. The COAD box plot shows higher SNORA71D RNA expression in tumor versus normal tissue (log2 FC = +1.112, t-test p < 0.001).
This table shows molecular features associated with SNORA71D in patient tissues and cancer cell lines. In patient samples, SNORA71D shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
